Take our survey

We value your opinion. To improve your experience on emend.com, we are conducting research to better understand the needs of our visitors.

Please take a few moments to complete a short 5-question survey.

Please be assured that this survey is for research purposes only and that your privacy will be respected. Your responses will remain strictly confidential.

Any data collected in this survey will be handled in accordance with the privacy policy of Vovici, who is administering this survey on behalf of Merck.

Your responses to this survey will be kept strictly confidential and WILL NOT be used to contact you or sell you products or information.

This survey is sponsored by Merck.

Take now Take later No thanks
Prevent Chemotherapy Nausea

The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
Merck

Despite treatment with a 5-HT3 receptor antagonist and a corticosteroid,
nausea & vomiting remains a serious problem.

Results from clinical trials show patients still suffer from chemotherapy-induced nausea and vomiting (CINV).

  • Highly emetogenic chemotherapy
  • Moderately emetogenic chemotherapy
  1. Reference:1.Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23(12):2822–2830.
20950402(6)-07/09-EME